The Type 1 hyperlipoproteinemia drugs market was valued at USD958.2Mn by 2019. As per the latest statistics provided by the National Organization for Rare Disorders (NORD), the global prevalence rate of type 1 hyperlipoproteinemia is 1 to 2 per 1,000,000 people. Strong product pipeline with revolutionary drugs will be employed in the treatment of type 1 hyperlipoproteinemia in the near future.

Type 1 hyperlipoproteinemia is also known as familial lipoprotein lipase deficiency, it is classified as a rare monogenetic rare disease in which there is excessive accumulation of triglycerides and chylomicrons in the human blood. Currently there is no FDA approved treatment regimen for this rare disease, however, drugs such as Alipogene Tiparvovec, lomitapide mesylate, pradigastat sodium, etc. are successfully employed in the treatment of type 1 hyperlipoproteinemia.

The major segments related to the type 1 hyperlipoproteinemia drugs market are:

By Indication (2017–2027; US$ Mn)

Hypertriglyceridemia

Pancreatitis

Eruptive Xanthomas

Others

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment(2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil

Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global type 1 hyperlipoproteinemia drugs market
• The overall segmentation of the type 1 hyperlipoproteinemia drugs market, by indication, distribution channel, and geography is minutely studied. Hypertriglyceridemia and hospital pharmacy are dominating the indication and distribution channel segments respectively
• Significant increase in the type 1 Hyperlipoproteinemia patients and constant rise in the deleterious health complications associate with its clinical manifestations urges for pharmacotherapy treatment
• Promising product pipeline and fast track status awarded by healthcare regulatory  agencies for drug development in the treatment of rare disease 

Report gist?

• The study of the global type 1 hyperlipoproteinemia drugs market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers qualitative and quantitative analysis of the overall market segmented on the basis of indication and distribution channel and categorization of the same at the geography level
• This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027
• The study includes the profiles of major market players with a significant global and regional presence along with top company positioning 

Significant customers?

• This study is suitable for industry participants and stakeholders in the biopharmaceutical companies engaged in manufacturing and marketing of drugs for treating the indications shown by type 1 hyperlipoproteinemia which is gaining huge demand on account of the rising prevalence of the rare disease and strong product pipeline for its treatment in the near future
• The report will benefit pharmacist engaged in compounding drugs for the treatment of type 1 hyperlipoproteinemia drugs
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to type 1 hyperlipoproteinemia drugs market
• Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Hypertriglyceridemia is reigning the indication segment for the type 1 hyperlipoproteinemia drug market. The inherent deficiency of the triglyceride metabolizing enzyme lipoprotein lipase causes the accumulation of triglyceride and chylomicrons in the blood plasma. It untreated presents risks for the occurrence of cardiovascular disease in the later parts of life. Acute pancreatitis is the first visible symptoms in patients suffering from lipoprotein lipase enzyme deficiency. The patients suffer from excruciating pain due to inflammation of the pancreas, if untreated it may be life-threatening and increases the risk of diabetes. Eruptive Xanthomas occurs in approximately 50% of the patients suffering from type 1 hyperlipoproteinemia, it is manifested by the occurrence of small bumps, or plaques on the skin surface due to localized deposition of lipids in the tendons, skin and subcutaneous tissues.

Hospital pharmacy is spearheading the distribution channel segment for the type 1 hyperlipoproteinemia drug market. Hospital pharmacist is necessary to compound the vital drugs prescribed for the treatment of orphan disease, in order to negate the occurrence of any drug-related adverse effects. Retail pharmacy is gaining huge demand in the developing countries on account of dispensing prescribed and OTC medicines 24/7 especially in remote locations.

North America is currently the largest geographical segment for the type 1 hyperlipoproteinemia drug market. As per the latest information brought forward by the National Institute of Health (NIH), annually in the United States more than 37,000 citizens are diagnosed with acute pancreatitis. Further diagnosis has revealed that it is linked with high levels of triglycerides in the blood. Proactive role adopted by the USFDA by awarding fast track designation status for the drug development to be used in the treatment of orphan disease further propels the type 1 hyperlipoproteinemia drug market. The market growth in the European region is primarily determined by the strategic research coloration between the academic research institutes and biopharmaceutical companies for drug development to treat lipoprotein lipase disorders. Additionally affordable reimbursement scenario for the drugs employed in the treatment of type 1 hyperlipoproteinemia accentuates its market growth in the region. Asia Pacific will be the fastest-growing regional segment during the forecast period owing to the developing healthcare infrastructure and huge government funds invested in research and development of orphan drugs.